With Rosetta Genomics prepping for an initial public offering during this year or next, it is set to join a handful of other companies in the RNAi drugs game that are traded on public markets. To date Alnylam Pharmaceuticals is the only firm to have floated its shares as an RNAi company; all the others were already public when they reorganized to focus on the gene-silencing technology.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.